Calliditas Signs a License Agreement with STADA to Commercialize Specialty Therapy for the Treatment of IgA Nephropathy in EU
Shots:
- Calliditas to receive $24M upfront and is eligible to receive ~$91M as regulatory and commercialization milestones along with royalties on net sales
- The companies collaborated to develop a new oral formulation that downregulates IgA1 by combining Calliditas' drug-delivery expertise with STADA's extensive marketing and sales platform for specialty and nephrology therapies
- The companies collaborated to bring a specialty therapy for IgAN in EU market- If approved- the therapy would be available to EU patients in H1’22 & would be the first approved treatment in the EU for chronic autoimmune kidney disease IgAN
| Ref: PR Newswire | Image: Pharmaceutical Technology
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com